Trials / Recruiting
RecruitingNCT06291987
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
A Phase 1b Trial of Ivosidenib Combined With Ruxolitinib in IDH1-Mutated Advanced-Phase MPNs
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this research is to gather information on the safety and effectiveness determining maximum tolerated dose (MTD) of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs while evaluate the efficacy of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ivosidenib | Ivosidenib will be given at assigned dose once daily. |
| DRUG | Ruxolitinib | Ruxolitinib will be given at assigned dose twice daily. |
Timeline
- Start date
- 2024-09-19
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
- First posted
- 2024-03-04
- Last updated
- 2025-11-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06291987. Inclusion in this directory is not an endorsement.